Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. cut its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,972 shares of the medical equipment provider’s stock after selling 187 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Intuitive Surgical were worth $1,340,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the business. Baystate Wealth Management LLC increased its holdings in Intuitive Surgical by 150.0% during the 4th quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 45 shares during the last quarter. MCF Advisors LLC raised its holdings in Intuitive Surgical by 108.1% in the fourth quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 40 shares in the last quarter. Atticus Wealth Management LLC boosted its stake in Intuitive Surgical by 85.4% during the 4th quarter. Atticus Wealth Management LLC now owns 89 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 41 shares during the last quarter. MeadowBrook Investment Advisors LLC acquired a new position in Intuitive Surgical during the 4th quarter worth $30,000. Finally, OFI Invest Asset Management bought a new stake in shares of Intuitive Surgical in the 3rd quarter worth about $25,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Trading Up 1.3 %

ISRG traded up $5.08 on Thursday, reaching $385.45. The company had a trading volume of 882,135 shares, compared to its average volume of 1,593,512. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $403.76. The company has a market capitalization of $136.72 billion, a P/E ratio of 69.58, a PEG ratio of 4.93 and a beta of 1.39. The company has a fifty day moving average of $385.21 and a 200-day moving average of $352.17.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.10. The business had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The business’s revenue was up 11.5% on a year-over-year basis. During the same period last year, the firm posted $1.00 earnings per share. Research analysts predict that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on ISRG shares. Citigroup lifted their price target on Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Jefferies Financial Group upped their price target on Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research report on Friday, April 19th. Wells Fargo & Company lifted their price objective on shares of Intuitive Surgical from $363.00 to $416.00 and gave the stock an “overweight” rating in a report on Friday, January 19th. Mizuho increased their target price on shares of Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a report on Thursday, January 25th. Finally, Stifel Nicolaus increased their price objective on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $396.17.

Insider Transactions at Intuitive Surgical

In related news, VP Marshall Mohr sold 108,790 shares of Intuitive Surgical stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the transaction, the vice president now directly owns 26,877 shares of the company’s stock, valued at $10,349,795.16. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Intuitive Surgical news, VP Marshall Mohr sold 108,790 shares of the company’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total value of $41,892,853.20. Following the transaction, the vice president now owns 26,877 shares of the company’s stock, valued at $10,349,795.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Mark J. Rubash sold 1,709 shares of the stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $380.00, for a total value of $649,420.00. Following the sale, the director now owns 16,051 shares of the company’s stock, valued at approximately $6,099,380. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 147,927 shares of company stock valued at $57,064,459. Corporate insiders own 0.80% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.